Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP – Free Report) – HC Wainwright issued their FY2027 earnings per share estimates for shares of Neuphoria Therapeutics Inc. – Common Stock in a report released on Tuesday, February 4th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($1.21) per share for the year. HC Wainwright currently has a “Buy” rating and a $21.00 target price on the stock. HC Wainwright also issued estimates for Neuphoria Therapeutics Inc. – Common Stock’s FY2028 earnings at ($1.36) EPS.
Neuphoria Therapeutics Inc. – Common Stock Stock Down 2.1 %
Shares of NEUP stock opened at $5.04 on Wednesday. Neuphoria Therapeutics Inc. – Common Stock has a twelve month low of $2.12 and a twelve month high of $16.08.
Neuphoria Therapeutics Inc. – Common Stock Company Profile
Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
Recommended Stories
- Five stocks we like better than Neuphoria Therapeutics Inc. – Common Stock
- What is the Nasdaq? Complete Overview with History
- Price Plunge in Roblox Presents Opportunity for Robust Gains
- Expert Stock Trading Psychology Tips
- Billions in Buybacks: 4 Stocks Rewarding Shareholders Now
- What is a Death Cross in Stocks?
- 3 Steel Stocks to Gain Strength as Tariffs Reshape the Market
Receive News & Ratings for Neuphoria Therapeutics Inc. - Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics Inc. - Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
